Introduction:

De novo protein sequencing of monoclonal antibodies is required when the cDNA or the original cell line is not available, or when characterization of posttranslational modifications is needed to verify antibody integrity and effectiveness. Complete Omics is proud to offer a series of unrivalled de novo antibody sequencing services for research, diagnostic and therapeutic industries. Complete Omics has developed the proprietary pipeline for antibody protein de novo seqeuncing, MyProt™-ABSeqs™, which is composed by conventional shotgun based database-dependent mass spectrometry sequencing method, and database-independent next generation proteomics de novo sequencing technologies, together with variant identification and de novo PTM profiling capacities.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, 2D gel spots, SDS-PAGE bands

2, Cell Lysates and Tissue Lysates

3, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details​.

4, FFPE slide/ FFPE extract

5, Customized sample types (please contact us to discuss)

Complete Omics Inc. Proudly Welcomes Proteomics Luminary Dr. Hui Zhang as Chief Scientific Officer

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the…

Read more

Securing a Brighter Future: Celebrating Our Investment from Qiming Venture Partners

November 25, 2023 | BALTIMORE –  Complete Omics management team are thrilled to announce a significant milestone for our company – a recent investment by Qiming Venture Partners. This partnership…

Read more

Complete Omics Inc. Founder Qing Wang Featured on Wharton Business School’s Official Website

July 27, 2023 | BALTIMORE –  Complete Omics is proud to announce a momentous occasion for Complete Omics Inc.: our visionary founder, Qing Wang, has been featured on the prestigious…

Read more

Some of our impacts